ABL1 and acute lymphoblastic leukemia: Furthermore, even open relapse of BCR-ABL+ ALL after alloSCT was successfully treated with addition of nilotinib and donor lymphocyte infusions underlining the efficacy of second-generation TKIs in addition to conventional therapy in this clinical scenario [15].